(Q41448726)

30 September 2017

1 reference

title

Trials and tribulations: oncological antibody imaging comes to the fore (English)

1 reference

30 September 2017

Zuckier LS

1

1 reference

30 September 2017

DeNardo GL

series ordinal

2

1 reference

30 September 2017

publication date

1 January 1997

1 reference

Seminars in Nuclear Medicine

30 September 2017

published in

1 reference

30 September 2017

volume

27

1 reference

30 September 2017

issue

1

1 reference

30 September 2017

page(s)

10-29

1 reference

The in vivo localization of anti-Wagner-osteogenic-sarcoma antibodies

30 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

European multicentre study on melanoma immunoscintigraphy by means of 99mTc-labelled monoclonal antibody fragments. The European Multicentre Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

Tumor imaging with monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

Preselection of patients with high TAG-72 antigen expression leads to targeting of 94% of known metastatic tumor sites with monoclonal antibody I-131-CC49

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

Quantitative studies of monoclonal antibody targeting to disialoganglioside GD2 in human brain tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

Practical considerations in the production, purification, and formulation of monoclonal antibodies for immunoscintigraphy and immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

Radiopharmaceuticals as orphan drugs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

Radiopharmaceutical regulation and Food and Drug Administration policy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

Imaging of colorectal carcinoma with radiolabeled antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

Site-specific covalent modification of monoclonal antibodies: in vitro and in vivo evaluations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

Role of In-111 labeled CYT-103 immunoscintigraphy in the evaluation of patients with recurrent colorectal carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

Immunoscintigraphy performed with In-111-labeled CYT-103 in the management of colorectal cancer: comparison with CT.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

Differences in tumour and normal tissue concentrations of iodine- and indium-labelled monoclonal antibody. I. The effect on image contrast in clinical studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

Radiolabeled antibody imaging in the management of colorectal cancer. Results of a multicenter clinical study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

111In-CYT-103 scanning in recurrent colorectal cancer--does it affect standard management?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

Specific carcinoembryonic antigens of the human digestive system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

Clinical utility of external immunoscintigraphy with the IMMU-4 technetium-99m Fab' antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum: results of a pivotal, phase III trial. The Immunomedics Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

Current status of cancer immunodetection with radiolabeled human monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

Imaging with indium111-labeled anticarcinoembryonic antigen monoclonal antibody ZCE-025 of recurrent colorectal or carcinoembryonic antigen-producing cancer in patients with rising serum carcinoembryonic antigen levels and occult metastases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

Detection of occult tumor using indium 111-labeled anticarcinoembryonic antigen antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

Monoclonal antibodies reactive with human breast or ovarian carcinoma: in vivo applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

New methods for imaging the breast: techniques, findings, and potential

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

A spectrum of monoclonal antibodies reactive with human mammary tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

Radioimmunolocalization of breast cancer using BrE-3 monoclonal antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

Monoclonal antibodies in ovarian and prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

Clinical assessment of 111In-CYT-103 immunoscintigraphy in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

Radioimmunoscintigraphy of ovarian tumours with technetium-99m labelled monoclonal antibody-170: first clinical experiences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

Imaging lung cancer with radiolabeled antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

Correlative image registration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

Radioimmunodetection of non-small cell lung cancer using technetium-99m-anticarcinoembryonic antigen IMMU-4 Fab' fragment. Preliminary results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

Radioimmunoscintigraphy of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

Radioimmunoscintigraphy of pelvic lymph nodes with 111indium-labeled monoclonal antibody CYT-356

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

Radioimmunoscintigraphy with 111indium labeled CYT-356 for the detection of occult prostate cancer recurrence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

Radioimmunotherapy of B-Cell Lymphoma with [131I]Anti-B1 (Anti-CD20) Antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

Lymphoma imaging with a new technetium-99m labelled antibody, LL2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

Current state of the hybridoma technology.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

Continuous cultures of fused cells secreting antibody of predefined specificity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

Immunologic and pharmacologic concepts of monoclonal antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

Recombinant antibodies possessing novel effector functions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

In vitro antibodies: strategies for production and application

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

Potential for recombinant immunoglobulin constructs in the management of carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

Bispecific monoclonal antibodies from hybrid hybridomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

Human monoclonal antibody production. Current status and future prospects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

Transfectomas provide novel chimeric antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

The immunogenicity of chimeric antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

Replacing the complementarity-determining regions in a human antibody with those from a mouse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

Reshaping human antibodies for therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

Reshaping human antibodies: grafting an antilysozyme activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

Generation of an antibody with enhanced affinity and specificity for its antigen by protein engineering

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

Humanized antibodies for therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

EB virus-induced B lymphocyte cell lines producing specific antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

Human X (mouse X human) hybridomas stably producing human antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

Production of fully human antibodies by transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

Strategies for expressing human antibody repertoires in transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

Localization of 131I-labeled p97-specific Fab fragments in human melanoma as a basis for radiotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

Single-chain antigen-binding proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

Development of biologically active peptides based on antibody structure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

Rapid evolution of peptide and protein binding properties in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

Recombinant polymeric IgG: an approach to engineering more potent antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

Structure and function of several anti-dansyl chimeric antibodies formed by domain interchanges between human IgM and mouse IgG2b.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

Recent developments in the radiolabeling of antibodies with iodine, indium, and technetium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

Positron emission tomography of monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

A novel technique for the production of hybrid antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

Recombinant interferon enhances monoclonal antibody-targeting of carcinoma lesions in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

The intraperitoneal delivery of radiolabeled monoclonal antibodies: studies on the regional delivery advantage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

The implications of decreased performance of new generation gamma-cameras on the interpretation of 131I-Hippuran renal images

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

inferred from DOI database lookup

7 January 2021

based on heuristic

Monoclonal antibody pretargetting techniques for tumour localization: the avidin-biotin system. International Workshop on Techniques for Amplification of Tumour Targetting

1 reference

https://api.crossref.org/works/10.1016%2FS0001-2998%2897%2980033-5

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0001-2998(97)80033-5

1 reference

30 September 2017

1 reference